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Introduction
Chronic migraine (CM) is a disabling neurological disor-
der that is defined in different ways. Treatment of CM is
difficult and needs multidisciplinary approach. To date,
minimal study of chronic migraine treatment has been
done and few medications are suggested to improve
headache duration and intensity in chronic migraine.
Different studies demonstrated that topiramate at a dose
of 100 mg/day, can reduce migraine days in CM patients
when compared with placebo.
Aims
The purpose of this double-blind, randomized trial was
to evaluate and compare the effects of extended-release
venlafaxine with topiramate in patients with chronic
migraine and medication overuse headache (MOH) to
investigate whether venlafaxine could be at least as
effective as topiramate.
Methods
Chronic migraine was defined according to the criteria
of the Headache Classification Committee of the Inter-
national Headache Society (IHS). A prospective, 4-week
run-in phase was followed by a 12-week treatment
phase which consistent of a 4-week titration and 8-week
maintenance period.
Results
There was no statistically significant difference in terms
of primary or secondary efficacy measures between
topiramate-group and venlafaxine-group during the
double-blind period.
Conclusions
In this double-blind, randomized study extended-release
venlafaxine 150 mg/day found to be effective in chronic
migraine. Our study showed a clear effect that was in
subgroup of subjects with medication overuse. In addi-
tion, in this study, the low number of adverse events
showed venlafaxine to be well tolerated. Future con-
trolled trials expended longer with larger sample size,
should also support the effectiveness and safety of venla-
faxine in patients suffering from chronic migraine.
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